CTOs on the Move


 
Indiva is a Canadian licensed producer of premium cannabis and cannabis products, and a provider of extraction, manufacturing and refinement services.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.indiva.com
  • 1050 Hargrieve Drive Unit 10
    London, ON CAN N6E 1P5
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Indiva raised $14M on 10/16/2019
Indiva raised $11M on 02/16/2021

Similar Companies

Artelon

Artelons technology was developed explicitly to enhance the strength and kinematic demands of reconstructed tendons and ligaments. Artelons Dynamic Matrix restores native motion, resists the necrotic degradation of  strength, and promotes an ideal me...

Caravel Autism Health

Caravel Autism Health provides early intervention to treat signs & symptoms of Autism. We serve families in Green Bay, Milwaukee, Madison, Wausau & Chicago.

Silence Therapeutics

Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.

Kyowa Hakko Kirin

Kyowa Kirin North America is a fully integrated specialty pharmaceutical company, where people work together to understand clinical needs and opportunities for innovation that can result in real advances for patients. Since 2018, the North American organization has received approval from the US Food and Drug Administration (FDA) to market 3 first-in-class medicines – achievements we share with the scientific, medical, and advocacy communities who contributed greatly to the success of these programs.